F. Bosch Et Al. , "Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)," 56th Annual Meeting of the American-Society-of-Hematology , vol.124, San-Francisco, Costa Rica, 2014
Bosch, F. Et Al. 2014. Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). 56th Annual Meeting of the American-Society-of-Hematology , (San-Francisco, Costa Rica).
Bosch, F., Illmer, T., Turgut, M., Cortelezzi, A., Lasserre, S. F., Truppel-Hartmann, A., ... Leblond, V.(2014). Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) . 56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica
Bosch, Francesc Et Al. "Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)," 56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 2014
Bosch, Francesc Et Al. "Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)." 56th Annual Meeting of the American-Society-of-Hematology , San-Francisco, Costa Rica, 2014
Bosch, F. Et Al. (2014) . "Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)." 56th Annual Meeting of the American-Society-of-Hematology , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={Francesc Bosch Et Al. }, title={Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)}, congress name={56th Annual Meeting of the American-Society-of-Hematology}, city={San-Francisco}, country={Costa Rica}, year={2014}}